Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
December 16, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration...
Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index
December 15, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
December 07, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
November 23, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
November 11, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
November 09, 2020 07:00 ET
|
Avadel Pharmaceuticals plc
NDA for once-nightly FT218 is on track for FDA submission by end of December 2020New market assessment data identifies a significant potential market expansion opportunity for once-nightly FT218...
Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th
October 26, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 17, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate,...
Avadel Pharmaceuticals Announces FT218 Leadership Transition
September 14, 2020 08:00 ET
|
Avadel Pharmaceuticals plc
Jordan Dubow, M.D. stepping down as CMO and will continue as a consultant to the Company through the FT218 NDA submission and reviewSeasoned industry veteran and Avadel Board member, Mark McCamish,...
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 11, 2020 16:35 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate,...